- Stocks
- Pharma & Healthcare
- Torrent Pharmaceuticals
Torrent Pharmaceuticals share price
NSE: TORNTPHARMPharma & HealthcareDrug Manufacturers - Specialty & Generic
Torrent Pharmaceuticals at a glance
Torrent Pharmaceuticals (NSE: TORNTPHARM) closed at ₹4,604.50 on 22 Oct 2026, up 1.31% on the day. With a market capitalisation of ₹1,75,140 Cr, it ranks 52nd by market cap among the 4,183 NSE companies Pivot tracks (a large-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 72.1× trailing earnings, against a return on equity of 25.8% in FY26. Over the past year the share price has risen 30.9%. Its 52-week range is ₹3,532.60 (6 Nov 2025) to ₹5,250.00 (3 Aug 2026); the last close is 12.3% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹4,835 Cr (+54.6% year on year) and net profit ₹566 Cr (+3.3%), on a consolidated basis. Promoters held 60.78% of the company as of 20 Jul 2026.
Key numbers
- Market cap
- ₹1,75,140 CrRank 52 on NSE
- P/E (trailing)
- 72.1×
- Price to book
- 17.03×FY26
- EPS (TTM)
- ₹62.60to Q1 FY27
- ROE
- 25.8%FY26
- ROCE
- 9.3%FY26
- Debt to equity
- 1.76FY26
- Net profit margin
- 15.3%FY26
- Book value / share
- ₹247.84FY26
- Dividend payout
- 54.8%FY26
- 52-week high
- ₹5,250.003 Aug 2026
- 52-week low
- ₹3,532.606 Nov 2025
- 1-year return
- +30.9%
- RSI (14-day)
- 40
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +1.31% | +0.6% | −7.4% | −8.6% | +30.9% |
Torrent Pharmaceuticals quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2,889 Cr | ₹2,809 Cr | ₹2,909 Cr | ₹3,128 Cr | ₹3,246 Cr | ₹3,251 Cr | ₹4,128 Cr | ₹4,835 Cr |
| Revenue YoY | +8.6% | +2.8% | +6.0% | +11.1% | +12.4% | +15.7% | +41.9% | +54.6% |
| Net profit | ₹453 Cr | ₹503 Cr | ₹498 Cr | ₹548 Cr | ₹591 Cr | ₹635 Cr | ₹364 Cr | ₹566 Cr |
| Net profit YoY | +17.4% | +13.5% | +10.9% | +19.9% | +30.5% | +26.2% | −26.9% | +3.3% |
| Net margin | 15.7% | 17.9% | 17.1% | 17.5% | 18.2% | 19.5% | 8.8% | 11.7% |
| EPS | ₹13.37 | ₹14.88 | ₹14.71 | ₹16.19 | ₹17.45 | ₹18.77 | ₹11.51 | ₹14.87 |
Torrent Pharmaceuticals financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹8,005 Cr | ₹8,508 Cr | ₹9,620 Cr | ₹10,728 Cr | ₹11,516 Cr | ₹13,980 Cr |
| Operating profit | ₹1,526 Cr | ₹1,711 Cr | ₹1,847 Cr | ₹2,264 Cr | ₹2,697 Cr | ₹2,961 Cr |
| Net profit | ₹1,252 Cr | ₹777 Cr | ₹1,245 Cr | ₹1,656 Cr | ₹1,911 Cr | ₹2,138 Cr |
| EPS (₹) | ₹74.00 | ₹46.00 | ₹37.00 | ₹49.00 | ₹56.00 | ₹64.00 |
| Cash from operations | ₹2,011 Cr | ₹1,803 Cr | ₹2,368 Cr | ₹3,266 Cr | ₹2,585 Cr | ₹3,023 Cr |
| Total debt | ₹2,941 Cr | ₹2,123 Cr | ₹2,496 Cr | ₹1,604 Cr | ₹1,192 Cr | ₹11,651 Cr |
| Shareholders' equity | ₹5,837 Cr | ₹5,953 Cr | ₹6,198 Cr | ₹6,856 Cr | ₹7,591 Cr | ₹8,388 Cr |
Torrent Pharmaceuticals shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 | 20 Jul 2026 |
|---|---|---|---|---|---|---|
| Promoters | 68.31% | 68.31% | 68.31% | 68.31% | 68.31% | 60.78% |
| Foreign institutions | 16.09% | 15.92% | 16.13% | 16.18% | 15.44% | 17.97% |
| Domestic institutions | 8.65% | 9.28% | 9.14% | 9.06% | 9.83% | 12.87% |
| Non-institutions | 6.94% | 6.49% | 6.42% | 6.45% | 6.42% | 8.38% |
Torrent Pharmaceuticals vs peers
The listed Pharma & Healthcare companies nearest to Torrent Pharmaceuticals by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | ₹1,744.40 | +0.33% | +5.6% | ₹4,18,540 Cr | 36.5 | — |
| DIVISLABDivi's Laboratories | ₹9,141.00 | +0.46% | +39.5% | ₹2,42,665 Cr | 94.6 | — |
| TORNTPHARMTorrent Pharmaceuticals | ₹4,604.50 | +1.31% | +30.9% | ₹1,75,140 Cr | 72.1 | — |
| ZYDUSLIFEZydus Lifesciences | ₹1,123.00 | +0.75% | +14.8% | ₹1,12,020 Cr | 22.4 | — |
| APOLLOHOSPApollo Hospitals Enterprise | ₹7,569.50 | −0.41% | −2.4% | ₹1,08,838 Cr | 56 | — |
| LAURUSLABSLaurus Labs | ₹2,010.10 | +0.02% | +129.8% | ₹1,08,596 Cr | 121.7 | — |
| CIPLACipla | ₹1,312.60 | +0.08% | −15.2% | ₹1,06,038 Cr | 27.3 | — |
Ask anything about Torrent Pharmaceuticals
Pivot answers on the live chart with evidence you can check, and tests strategies against TORNTPHARM's own history. Try: “Why has TORNTPHARM moved over the last three months?” · “Backtest a 50-day moving-average crossover on TORNTPHARM over five years” · “Compare TORNTPHARM with SUNPHARMA on margins and valuation”
Frequently asked questions about Torrent Pharmaceuticals
What is the share price of Torrent Pharmaceuticals today?
Torrent Pharmaceuticals (NSE: TORNTPHARM) last closed at ₹4,604.50 on 22 Oct 2026. Its 52-week high is ₹5,250.00 and its 52-week low is ₹3,532.60.
What is the market cap of Torrent Pharmaceuticals?
Torrent Pharmaceuticals' market capitalisation is ₹1,75,140 Cr (₹1.75 lakh Cr) at the 22 Oct 2026 close, ranking 52nd among the NSE companies Pivot tracks.
What is the P/E ratio of Torrent Pharmaceuticals?
Torrent Pharmaceuticals trades at a trailing P/E of 72.1. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 56.
What is the ROE and ROCE of Torrent Pharmaceuticals?
Return on equity was 25.8% in FY26 and return on capital employed was 9.3% in FY26 (consolidated figures).
Is Torrent Pharmaceuticals a debt-free company?
No. Torrent Pharmaceuticals' debt-to-equity ratio was 1.76 in FY26, with total debt of ₹11,651 Cr.
What were Torrent Pharmaceuticals' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Torrent Pharmaceuticals reported revenue of ₹4,835 Cr, +54.6% year on year, and net profit of ₹566 Cr, +3.3% year on year.
How has Torrent Pharmaceuticals stock performed over the last year?
Torrent Pharmaceuticals' share price has risen 30.9% over the past year, −8.6% over three months and −7.4% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Torrent Pharmaceuticals?
As of 20 Jul 2026: promoters 60.78%, foreign institutions 17.97%, domestic institutions 12.87%, non-institutions 8.38%.
Who are Torrent Pharmaceuticals' competitors?
The listed Pharma & Healthcare companies closest to Torrent Pharmaceuticals by market cap are Sun Pharmaceutical Industries, Divi's Laboratories, Zydus Lifesciences, Apollo Hospitals Enterprise, Laurus Labs and Cipla.
Is Torrent Pharmaceuticals a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Torrent Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on TORNTPHARM against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with T · all NSE stocks · this page as text